Nuvectis Pharma FY2026 EPS Estimate Cut by HC Wainwright

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Analysts at HC Wainwright decreased their FY2026 earnings estimates for Nuvectis Pharma in a report issued on Wednesday, February 11th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($1.23) for the year, down from their prior estimate of ($1.08). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s FY2027 earnings at ($1.28) EPS and FY2028 earnings at ($1.54) EPS.

Nuvectis Pharma (NASDAQ:NVCT) last released its earnings results on Wednesday, February 11th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.05).

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Nuvectis Pharma in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Nuvectis Pharma has an average rating of “Moderate Buy” and an average target price of $15.33.

Nuvectis Pharma Trading Down 0.5%

NASDAQ:NVCT opened at $8.76 on Friday. Nuvectis Pharma has a 12 month low of $5.55 and a 12 month high of $11.52. The firm’s 50 day moving average is $8.18 and its 200 day moving average is $6.95. The stock has a market capitalization of $232.05 million, a PE ratio of -6.64 and a beta of -0.29.

Institutional Trading of Nuvectis Pharma

A number of institutional investors have recently added to or reduced their stakes in NVCT. Police & Firemen s Retirement System of New Jersey purchased a new position in Nuvectis Pharma during the 2nd quarter valued at about $28,000. JPMorgan Chase & Co. lifted its holdings in shares of Nuvectis Pharma by 3,398.9% in the second quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock worth $47,000 after buying an additional 6,084 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Nuvectis Pharma in the second quarter valued at approximately $53,000. Avalon Trust Co purchased a new position in Nuvectis Pharma during the third quarter valued at approximately $60,000. Finally, Bank of America Corp DE increased its holdings in Nuvectis Pharma by 417.2% during the 2nd quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock worth $64,000 after acquiring an additional 6,909 shares during the period. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.